Table 2 Storage stability of NCAB and NM2CAB nanoformulations.

From: Lipophilic nanocrystal prodrug-release defines the extended pharmacokinetic profiles of a year-long cabotegravir

  

NCAB

NM2CAB

 

Time (Day)

Stability

% Release

Stability

% Release

Neat

0

90.0%

35.8%

112.3%

7.4%

4

88.9%

38.4%

95.2%

6.7%

7

103.2%

30.0%

83.6%

10.8%

14

102.4%

26.0%

92.7%

7.0%

30

100.5%

24.1%

95.8%

8.1%

60

95.8%

39.3%

108.4%

6.2%

90

95.3%

32.5%

94.3%

8.4%

252

95.9%

37.6%

112.2%

6.3%

365

111.7%

26.4%

100.8%

5.0%

20×-diluted

0

110.4%

29.8%

94.8%

7.9%

4

106.5%

26.5%

84.3%

9.7%

7

101.5%

30.8%

87.1%

8.6%

14

111.3%

23.7%

106.8%

6.1%

30

101.4%

25.0%

86.9%

8.6%

60

114.8%

20.3%

116.1%

7.0%

90

105.5%

22.1%

105.6%

7.4%

252

102.7%

31.1%

102.3%

8.5%

365

101.6%

36.2%

102.3%

5.4%

  1. Stability of NCAB and NM2CAB at 36.7 and 55.4 mg/ml (undiluted), and 1.835 and 2.77 mg/ml (20×-diluted), respectively.